Table 1. Body composition assessed by dual-energy X-ray absorptiometry and computerized axial tomography in a subgroup of participants at 20 weeks.

	Placebo n=14	Liraglutide				Orlistat n=12
		1.2 mg n=15	1.8 mg n=13	2.4 mg n=15	3.0 mg n=15
Dual-energy X-ray absorptiometry measurements: body composition at randomization (kg)a
Fat tissue	45.8 (10.5)	43.5 (7.6)	45.0 (8.8)	42.6 (6.1)	43.9 (8.4)	41.3 (6.7)
Lean tissue	51.0 (11.0)	55.0 (8.9)	51.7 (11.3)	50.6 (11.9)	53.1 (10.3)	47.4 (6.4)
Relative change at week 20 (%)
Fat tissueb	−11.9 (2.5)	−13.9 (2.7)	−13.0 (2.6)	−16.5 (2.5)	−15.4 (2.6)	−13.3 (2.9)
Change vs placeboc	—	−2.0 (−8.9 to 4.9); P=0.57	−1.1 (−8.0 to 5.9); P=0.76	−4.6 (−11.2 to 2.1); P=0.18	−3.5 (−10.3 to 3.4); P=0.32	—
Lean tissueb	−1.3 (1.0)	−0.9 (1.1)	−2.9 (1.1)	−2.6 (1.0)	−2.0 (1.1)	0.9 (1.2)
Change vs placeboc	—	0.4 (−2.4 to 3.3); P=0.77	−1.6 (−4.4 to 1.3); P=0.28	−1.3 (−4.1 to 1.4); P=0.33	−0.7 (−3.6 to 2.1); P=0.61	—
Computerized axial tomography measurements: body composition at randomization (cm2)a
Visceral fat	136 (38)	172 (77)	121 (39)	149 (76)	145 (69)	101 (40)
Subcutaneous fat	474 (107)	453 (68)	476 (71)	426 (75)	434 (116)	459 (113)
Relative change at week 20 (%)
Visceral fatb	−13.8 (5.7)	−19.0 (6.3)	−19.4 (6.0)	−23.0 (5.7)	−20.3 (6.0)	−20.2 (6.7)
Change vs placeboc	—	−5.1 (−21.2 to 11.0); P=0.53	−5.6 (−21.8 to 10.6); P=0.49	−9.2 (−24.7 to 6.4); P=0.25	−6.4 (−22.1 to 9.2); P=0.42	—
Subcutaneous fatb	−12.1 (3.0)	−15.6 (3.3)	−15.9 (3.6)	−19.3 (3.0)	−15.3 (3.3)	−17.9 (3.6)
Change vs placeboc	—	−3.5 (−11.8 to 4.9); P=0.41	−3.8 (−12.6 to 5.1); P=0.40	−7.1 (−15.2 to 1.0); P=0.09	−3.1 (−11.5 to 5.2); P=0.45	—

^aMean (s.d.).

^bEstimated mean (s.e.).

^cEstimated mean (95% CI); P-value.

Values are for participants who completed the substudy according to the protocol (PP completers).